Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07308574) titled 'Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Alexion Pharmaceuticals, Inc.
Condition:
aHUS
Atypical Hemolytic Uremic Syndrome
Intervention:
Drug: Ravulizumab
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: December 26, 2025
Target Sample Size: 20
Countries of Recruitment:
Japan
To know more, visit https://clinicaltrials.gov/study/NCT07308574
Publi...